MedTrace Logo

Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy

NCT07122466 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2025-08-14

No results posted yet for this study

Summary

This is a study that aims to understand whether a blood test measuring tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA) shows a similar response as observed by a follow-up CT scan. To study this question, ctDNA will be measured at the same times as CT scans (just before the start of treatment, as well as 2 months after), and the response measured by the ctDNA change will be compared to the response seen on the changes between the CT scans. The goal is to make sure that ctDNA response correlates well with CT scan response measurement.

Conditions

Interventions

DIAGNOSTIC_TEST

Tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA)

ctDNA will be measured at the same times as CT scans (just before the start of treatment, as well as 2 months after), and the response measured by the ctDNA change will be compared to the response seen on the changes between the CT scans. The goal is to make sure that ctDNA response correlates well with CT scan response measurement.

Sponsors & Collaborators

  • Northwell Health

    lead OTHER

Principal Investigators

  • Daniel King, MD · Northwell Health

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-22
Primary Completion
2023-10-17
Completion
2025-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07122466 on ClinicalTrials.gov